ANALYSIS OF KARYOTYPE, SCE, AND POINT MUTATION OF RAS ONCOGENE IN INDIAN MDS PATIENTS

被引:14
作者
MANSOOR, AM
BHARADWAJ, TPR
SETHURAMAN, S
CHANDY, M
PUSHPA, V
KAMADA, N
MURTHY, PBK
机构
[1] FREDRICK INST PLANT PROTECT & TOXICOL,PADAPPAI 601301,TAMIL NADU,INDIA
[2] HIROSHIMA UNIV,NUCL MED & BIOL RES INST,DEPT HEMATOL,HIROSHIMA 730,JAPAN
[3] UNIV MADRAS,MADRAS MED COLL,DEPT HEMATOL,MADRAS 600007,TAMIL NADU,INDIA
[4] INST CHILD HLTH,DEPT HEMATOL,MADRAS,INDIA
[5] CHRISTIAN MED COLL & HOSP,DEPT HEMATOL,VELLORE,TAMIL NADU,INDIA
关键词
D O I
10.1016/0165-4608(93)90052-N
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Thirty Indian patients diagnosed as having primary myelodysplastic syndrome as per the French-American-British classification were investigated, on admission, for the frequencies of nonrandom karyotype abnormalities, sister chromatid exchange, and point mutations of the RAS oncogene. Successful karyotype analysis was possible in 24 patients, of whom 9 (37.5%) showed nonrandom karyotypic changes. Anomalies of chromosomes 5, 7, and 8 were detected in their bone marrow (BM). In addition, two new anomalies, del(8)(q22) and +19, were observed for the first time in our series. Six MDS patients were studied for SCE in either BM or peripheral blood. These data revealed a normal SCE incidence. Of the 10 MDS patients studied for point mutations of NRAS 12 and 61 and KRAS 12 and 61, one patient exhibited a base substitution at position 1 of the 12th codon of the KRAS gene. These data, gathered for the first time on the Indian patients, throw some light on the nature of genetic changes in MDS of our country.
引用
收藏
页码:12 / 20
页数:9
相关论文
共 48 条
[1]   CYTOGENETIC STUDY OF 88 CASES OF REFRACTORY-ANEMIA [J].
AYRAUD, N ;
DONZEAU, M ;
RAYNAUD, S ;
LAMBERT, JC .
CANCER GENETICS AND CYTOGENETICS, 1983, 8 (03) :243-248
[2]  
BAIN BJ, 1990, LEUKEMIA DIAGNOSIS G, P44
[3]   ONCOGENE ACTIVATION IN CHEMICAL CARCINOGENESIS [J].
BALMAIN, A ;
BROWN, K .
ADVANCES IN CANCER RESEARCH, 1988, 51 :147-182
[4]   PROPOSALS FOR THE CLASSIFICATION OF THE MYELODYSPLASTIC SYNDROMES [J].
BENNETT, JM ;
CATOVSKY, D ;
DANIEL, MT ;
FLANDRIN, G ;
GALTON, DAG ;
GRALNICK, HR ;
SULTAN, C .
BRITISH JOURNAL OF HAEMATOLOGY, 1982, 51 (02) :189-199
[5]  
BILLSTROM R, 1986, SCAND J HAEMATOL, V37, P29
[6]  
BOS JL, 1990, MOL GENETICS CANCER, P273
[7]  
BURCK KB, 1988, ONCOGENES INTRO CONC
[8]   MARROW CYTOGENETIC AND CELL-CULTURE ANALYSES OF THE MYELODYSPLASTIC SYNDROMES - INSIGHTS TO PATHO-PHYSIOLOGY AND PROGNOSIS [J].
GOLD, EJ ;
CONJALKA, M ;
PELUS, LM ;
JHANWAR, SC ;
BROXMEYER, H ;
MIDDLETON, AB ;
CLARKSON, BD ;
MOORE, MAS .
JOURNAL OF CLINICAL ONCOLOGY, 1983, 1 (10) :627-634
[9]  
GOLDBERG H, 1990, CANCER RES, V50, P6876
[10]   PROGNOSTIC VALUE OF CLONAL CHROMOSOMAL-ABNORMALITIES IN PATIENTS WITH PRIMARY MYELODYSPLASTIC SYNDROMES [J].
GYGER, M ;
INFANTERIVARD, C ;
DANGELO, G ;
FOREST, L ;
LUSSIER, P .
AMERICAN JOURNAL OF HEMATOLOGY, 1988, 28 (01) :13-20